Mission Bio, a leader in single-cell multi-omics, today announced Tapestri® Triomics, a new expansion of the Tapestri Platform that simultaneously analyzes DNA, RNA, and protein in the same cell. By ...
Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") today announced that they have signed a research collaboration and license agreement to advance MDL-201, an innovative ...
Explore a new class of spatial technology for use with formalin-fixed paraffin-embedded (FFPE) samples. This workflow ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of the ddSEQ™ Single-Cell 3' RNA-Seq Kit and ...
PHILADELPHIA--(BUSINESS WIRE)--Exegenesis Bio, a rapidly growing global genetic medicines company, is pleased to announce the presentation of clinical efficacy and safety data from its EXG001-307 ...
The cell and gene therapy field is, some say, at a tipping point—poised to take off. The FDA has noted that, by next year, they aim to approve 10–20 new cell and gene therapies per year. To do that, ...
A Cambridge, Massachusetts biotechnology company dosed the first child in the world to receive an experimental gene therapy targeting GJB2 — the single most common genetic cause of childhood deafness ...
Research has uncovered a previously unknown, widespread role of ORC in regulating human cell gene expression. New work has revealed a much wider role for origin-recognition complex (ORC) in regulating ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results